Outcomes Related to FDG-PET-CT Response in Patients With Hodgkin Lymphoma Treated With Brentuximab-Vedotin at Relapse or Consolidation |
| |
| Institution: | 1. Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel;2. Sackler School of Medicine, Tel-Aviv university, Tel-Aviv, Israel;3. The Mina & Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel;1. University Hospitals Cleveland Medical Center, Department of Internal Medicine, Cleveland, OH;2. University of Arizona, Department of Internal Medicine, Tucson, AZ;3. Beth Israel Deaconess Medical Center, Department of Internal Medicine, Boston, MA;4. Case Western Reserve University School of Medicine, Health Education Campus, Cleveland, OH;5. University of Pittsburgh Medical Center - McKeesport, Department of Internal Medicine, McKeesport, PA;6. Cleveland Clinic Taussig Cancer Center, Cleveland, OH;7. Beth Israel Deaconess Medical Center, Knowledge Services, Boston, MA;8. Cleveland Clinic, Division of Hematology and Oncology, Cleveland, OH;1. National Research Center for Hematology, Moscow, Russia;2. S.P. Botkin City Hospital, Moscow, Russia;1. Department of Radiology, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan;2. Department of Radiology, National Hospital Organization Tokyo Medical Center, Meguro-ku, Tokyo, Japan;1. Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL;2. Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine and Robert H Lurie Comprehensive Cancer Center, Chicago, IL;1. Department of Clinical Hematology and Cellular Therapy, Saint Antoine Hospital, INSERM UMR 938, Sorbonne University, Paris, France;2. Department of Internal Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, New York, NY;3. Department for Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany;4. German Clinic for Diagnistics, KMT Zentrum, Wiesbaden, Germany;5. Departement D''Hematologie, Programme de Transplantation et de Therapie Cellulaire, Centre de Recherche en Cancerologie de Marseille, Institut Paoli Calmettes, Marseille, France;6. Department of Internal Medicine I, Ordensklinikum Linz -Elisabethinen, Linz, Austria;7. Clinica Ematologica, Azienda sanitaria Universitaria Integrata, DAMe, Università di Udine, Udine, Italy;8. Department of Internal Medicine II, University Hospital Würzburg, Germany;9. Departments of Oncology-Hematology, Ospedale \"G. da Saliceto\", Piacenza, Italy;10. Stem Cell Transplantation Unit, HUCH Comprehensive Cancer Center, Helsinki, Finland;11. Hematology Department, Grenoble Alpes University Hospital, Grenoble, France;12. Department of Hematology and Oncology, Städtisches Klinikum Karlsruhe, Karlsruhe, Germany;13. Department of Medicine II, Goethe University, Frankfurt, Germany;14. Department of Internal Medicine I, University Hospital Cologne, Cologne, Germany;15. 3rd Medical Department, Hematology, Oncology and Pneumology, University Medical Center Mainz, Mainz, Germany;16. Medizinische Klinik und Poliklinik I, Universitätsklinikum, Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany;17. Department of Internal Medicine, American University of Beirut, Beirut, Lebanon;18. Vanderbilt University Medical Center, Nashville, TN;19. Hematology Division, Chaim Sheba Medical Center, Tel Hashomer, Israel |
| |
| Abstract: | BackgroundBrentuximab-vedotin (BV) monotherapy has shown high efficacy in heavily pre-treated patients with relapsed or refractory Hodgkin lymphoma (HL) after high-dose chemotherapy or autologous stem cell transplantation (ASCT). We retrospectively analyzed the outcomes of treatment with BV of HL patients and examined the predictive ability of PET-CT for response in this setting.Patients and methodsRecords of 49 HL patients (median age, 39 years, 55% male) treated with BV for relapse (71.4%) or consolidation (28.6%) post-ASCT were analyzed. Patients who did not reach complete response (CR) on PET/CT after 4 cycles (non-responders) discontinued BV and received the next treatment line. Overall survival (OS) and progression-free survival (PFS) were compared between responders and non-responders.ResultsAfter a median follow-up of 19.1 months, all consolidation patients were alive and none progressed. Median OS in 23 relapsed patients that did not achieve CR after 4 cycles and continued to the next treatment was 55.0 months, while all those in CR (n = 24) were alive (P = .0120). No statistically significant differences in OS were observed between responders and non-responders with relapsed HL (P = .1072). Median PFS evaluated after 4 BV cycles was significantly longer in responders compared to non-responders (47.9 vs. 1.5 months, P < .0001). Neuropathy and neutropenia were the main toxicities observed.ConclusionsHL patients treated with BV for relapse or consolidation who achieved CR by PET-CT after 4 cycles showed improved PFS and OS compared to non-responders. Non-responders treated for relapsed HL who proceeded to the next treatment line demonstrated comparable OS to responders. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
